KINNATE BIOPHARMA INC (KNTE) Fundamental Analysis & Valuation

NASDAQ:KNTE • US49705R1059

2.65 USD
-0.01 (-0.38%)
At close: Apr 2, 2024
2.65 USD
0 (0%)
After Hours: 4/2/2024, 8:25:40 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This KNTE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KNTE. KNTE was compared to 519 industry peers in the Biotechnology industry. KNTE has a great financial health rating, but its profitability evaluates not so good. KNTE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. KNTE Profitability Analysis

1.1 Basic Checks

  • KNTE had negative earnings in the past year.
  • In the past year KNTE has reported a negative cash flow from operations.
  • In the past 5 years KNTE always reported negative net income.
  • KNTE had a negative operating cash flow in each of the past 5 years.
KNTE Yearly Net Income VS EBIT VS OCF VS FCFKNTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of KNTE (-64.89%) is worse than 62.35% of its industry peers.
  • The Return On Equity of KNTE (-70.70%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -64.89%
ROE -70.7%
ROIC N/A
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
KNTE Yearly ROA, ROE, ROICKNTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

  • KNTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KNTE Yearly Profit, Operating, Gross MarginsKNTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. KNTE Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, KNTE has more shares outstanding
  • KNTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KNTE Yearly Shares OutstandingKNTE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
KNTE Yearly Total Debt VS Total AssetsKNTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of 1.00, we must say that KNTE is in the distress zone and has some risk of bankruptcy.
  • With a decent Altman-Z score value of 1.00, KNTE is doing good in the industry, outperforming 64.57% of the companies in the same industry.
  • KNTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1
ROIC/WACCN/A
WACCN/A
KNTE Yearly LT Debt VS Equity VS FCFKNTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

  • KNTE has a Current Ratio of 13.19. This indicates that KNTE is financially healthy and has no problem in meeting its short term obligations.
  • KNTE's Current ratio of 13.19 is amongst the best of the industry. KNTE outperforms 86.88% of its industry peers.
  • KNTE has a Quick Ratio of 13.19. This indicates that KNTE is financially healthy and has no problem in meeting its short term obligations.
  • KNTE has a better Quick ratio (13.19) than 87.05% of its industry peers.
Industry RankSector Rank
Current Ratio 13.19
Quick Ratio 13.19
KNTE Yearly Current Assets VS Current LiabilitesKNTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. KNTE Growth Analysis

3.1 Past

  • KNTE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.68%, which is quite good.
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • KNTE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.70% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNTE Yearly Revenue VS EstimatesKNTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 50M 100M 150M 200M 250M
KNTE Yearly EPS VS EstimatesKNTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. KNTE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KNTE. In the last year negative earnings were reported.
  • Also next year KNTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KNTE Price Earnings VS Forward Price EarningsKNTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNTE Per share dataKNTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

  • KNTE's earnings are expected to grow with 13.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.83%
EPS Next 3Y13.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KNTE Dividend Analysis

5.1 Amount

  • KNTE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

KNTE Fundamentals: All Metrics, Ratios and Statistics

KINNATE BIOPHARMA INC

NASDAQ:KNTE (4/2/2024, 8:25:40 PM)

After market: 2.65 0 (0%)

2.65

-0.01 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28
Earnings (Next)05-09
Inst Owners0.91%
Inst Owner Change0%
Ins Owners6.99%
Ins Owner Change0%
Market Cap125.00M
Revenue(TTM)N/A
Net Income(TTM)-112.65M
Analysts78
Price Target2.41 (-9.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.27%
Min EPS beat(2)5.59%
Max EPS beat(2)16.95%
EPS beat(4)4
Avg EPS beat(4)8.9%
Min EPS beat(4)1.96%
Max EPS beat(4)16.95%
EPS beat(8)7
Avg EPS beat(8)3.8%
EPS beat(12)7
Avg EPS beat(12)0.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.35%
PT rev (3m)-12.47%
EPS NQ rev (1m)1.14%
EPS NQ rev (3m)5.3%
EPS NY rev (1m)0%
EPS NY rev (3m)9.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-2.42
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS0
BVpS3.38
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.89%
ROE -70.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.19
Quick Ratio 13.19
Altman-Z 1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)365%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.09%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.37%
OCF growth 3YN/A
OCF growth 5YN/A

KINNATE BIOPHARMA INC / KNTE FAQ

What is the ChartMill fundamental rating of KINNATE BIOPHARMA INC (KNTE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KNTE.


What is the valuation status for KNTE stock?

ChartMill assigns a valuation rating of 0 / 10 to KINNATE BIOPHARMA INC (KNTE). This can be considered as Overvalued.


What is the profitability of KNTE stock?

KINNATE BIOPHARMA INC (KNTE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for KINNATE BIOPHARMA INC?

The Earnings per Share (EPS) of KINNATE BIOPHARMA INC (KNTE) is expected to grow by 47.95% in the next year.